EBMT 2019 | The value of MRD testing in transplant-eligible patients

Maria-Victoria Mateos

MRD testing has proven to be significant in determining treatment endpoint in patients with multiple myeloma. Here, Maria-Victoria Mateos, MD, PhD, of University Hospital of Salamanca, Salamanca, Spain, talks about the value of MRD testing in transplant-eligible patients. Dr Mateos was speaking at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.

Share this video